X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (206) 206
index medicus (173) 173
oncology (172) 172
male (128) 128
respiratory system (128) 128
female (125) 125
middle aged (116) 116
chemotherapy (110) 110
aged (109) 109
lung cancer (107) 107
lung neoplasms - drug therapy (98) 98
carcinoma, non-small-cell lung - drug therapy (92) 92
cancer (89) 89
adult (85) 85
lung neoplasms - pathology (82) 82
life sciences (60) 60
carcinoma, non-small-cell lung - pathology (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
aged, 80 and over (52) 52
lung cancer, non-small cell (52) 52
treatment outcome (50) 50
docetaxel (42) 42
lung neoplasms - mortality (42) 42
non-small cell lung cancer (42) 42
care and treatment (37) 37
open-label (37) 37
prognosis (37) 37
surgery (37) 37
neoplasm staging (36) 36
survival (36) 36
hematology, oncology and palliative medicine (35) 35
carcinoma, non-small-cell lung - mortality (33) 33
nsclc (33) 33
trial (33) 33
antineoplastic agents - therapeutic use (32) 32
carboplatin (32) 32
cisplatin (31) 31
gefitinib (30) 30
therapy (30) 30
disease-free survival (29) 29
survival analysis (29) 29
multicenter (27) 27
bevacizumab (26) 26
erlotinib (26) 26
metastasis (26) 26
mutation (26) 26
patients (26) 26
cell lung-cancer (24) 24
immunotherapy (24) 24
lung neoplasms - surgery (24) 24
biomarkers (23) 23
lung neoplasms - genetics (23) 23
survival rate (23) 23
crizotinib (22) 22
adenocarcinoma (21) 21
non-small cell lung carcinoma (21) 21
non-small-cell lung cancer (21) 21
quality of life (21) 21
carcinoma, non-small-cell lung - genetics (20) 20
paclitaxel (20) 20
research (20) 20
tumors (20) 20
1st-line treatment (19) 19
cardiac & cardiovascular systems (19) 19
follow-up studies (19) 19
nivolumab (19) 19
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
clinical trials (18) 18
diagnosis (18) 18
gemcitabine (18) 18
lung neoplasms - therapy (18) 18
retrospective studies (18) 18
analysis (17) 17
cisplatin - administration & dosage (17) 17
france (17) 17
pemetrexed (17) 17
egfr (16) 16
medicine, general & internal (16) 16
prospective studies (16) 16
protein kinase inhibitors - therapeutic use (16) 16
[sdv.can]life sciences [q-bio]/cancer (15) 15
cancer therapies (15) 15
carcinoma, non-small-cell lung - surgery (15) 15
carcinoma, non-small-cell lung - therapy (15) 15
combination (15) 15
deoxycytidine - analogs & derivatives (15) 15
growth-factor receptor (15) 15
quality-of-life (15) 15
young adult (15) 15
adenocarcinoma - drug therapy (14) 14
carcinoma (14) 14
radiotherapy (14) 14
risk factors (14) 14
kaplan-meier estimate (13) 13
lung neoplasms (13) 13
lung neoplasms - diagnosis (13) 13
metastases (13) 13
supportive care (13) 13
vinorelbine (13) 13
[ sdv.can ] life sciences [q-bio]/cancer (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 24, pp. 2288 - 2301
... for those with nonsquamous cancer. 5 However, the prognosis remains poor. The anti–PD-L1 antibody atezolizumab (Tecentriq, F. Hoffmann–La Roche/Genentech) 6 , 7 has been shown... 
PHASE-III TRIAL | CELLS | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 7, pp. 629 - 640
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2017, Volume 12, Issue 11, pp. S1677 - S1677
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1525 - 1531
Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in... 
Internal Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | THERAPY | CISPLATIN | COMBINATION | GEMCITABINE | ERLOTINIB | PACLITAXEL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Proportional Hazards Models | Survival Rate | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy | Research | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer | Drugs | Studies | Data analysis | Lung cancer | Acne | Monoclonal antibodies | Clinical medicine | Kinases | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 17, pp. 1627 - 1639
Journal Article